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ErbB receptors are important regulators of fetal organ development, including the fetal lung. They exhibit diversity in signaling potential,
acting through homo- and heterodimers to cause different biological responses. We hypothesized that ErbB receptors show cell-specific and
stimuli-specific activation, heterodimerization, and cellular localization patterns in fetal lung. We investigated this using immunoblotting, co-
immunoprecipitation, and confocal microscopy in primary isolated E19 fetal rat lung fibroblasts and epithelial type II cells, stimulated with
epidermal growth factor, transforming growth factor α, neuregulin 1β, or treated with conditioned medium (CM) from the respective other cell
type. Fetal type II cells expressed significantly more ErbB1, ErbB2, and ErbB3 protein than fibroblasts. ErbB4 was consistently identified by co-
immunoprecipitation of all other ErbB receptors in both cell types independent of the treatments. Downregulation of ErbB4 in fibroblasts initiated
cell–cell communication that stimulated surfactant phospholipid synthesis in type II cells. Confocal microscopy in type II cells revealed nuclear
localization of all receptors, most prominently for ErbB4. Neuregulin treatment resulted in relocation to the extra-nuclear cytoplasmic region,
which was distinct from fibroblast CM treatment which led to nuclear localization of ErbB4 and ErbB2, inducing co-localization of both receptors.
We speculate that ErbB4 plays a prominent role in fetal lung mesenchyme–epithelial communication.
© 2007 Elsevier B.V. All rights reserved.Keywords: Neuregulin; Epidermal growth factor; Transforming growth factor α; Conditioned medium; Lung development1. Introduction
The four members of the ErbB receptor family (epidermal
growth factor receptor (EGFR)/ErbB1, ErbB2, ErbB3 and
ErbB4) are transmembrane tyrosine kinases with structural
homologies [32]. ErbB receptor signaling leads to a diversity of
biologic effects during embryonic development. Through
interaction with each other the receptors form an array of
homo- and heterodimers leading to signal diversification that
permits ErbB receptors to control developmental processes in
diverse tissues [1]. The importance of ErbB receptors in
development has been demonstrated in knockout mouse models
for each receptor. Loss of ErbB1 leads to an overall pulmonary
epithelial immaturity, including impaired branching, deficient
alveolarization, reduced surfactant protein, and a marked⁎ Corresponding author. Tel.: +1 617 636 5054; fax: +1 617 636 4233.
E-mail address: wliu2@tufts-nemc.org (W. Liu).
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doi:10.1016/j.bbadis.2007.04.008reduction in alveolar volume in the lung [21]. ErbB2 null
mice die at mid-gestation (E10.5) due to central nervous system
and cardiac malformations [18], a phenotype that is shared by
ErbB4 knockout mice [12]. Most ErbB3 knock out mice die by
E13.5 and have gross malformations of the nervous system and
Schwann cells. A few embryos survive to birth but die shortly
afterwards of respiratory insufficiency and exhibit uninflated
lungs [33]. The early embryonic lethality of the ErbB knockout
models precludes developing any information on ErbB receptor
involvement in late gestation lung maturation.
ErbB ligands are involved in lung maturation. The mRNA
transcripts of epidermal growth factor (EGF) and transforming
growth factor-alpha (TGFα) are expressed in fetal lung mesen-
chymal cells [35]. EGF and TGFα, the ligands for ErbB1,
positively influence surfactant synthesis through mesenchymal–
epithelial cell communication [24,25], whereas neuregulin (NRG)
1β, the ligand for ErbB3 and ErbB4 [4], is secreted by fetal lung
fibroblasts and stimulates surfactant synthesis directly in the fetal
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antibodies to NRG1β [8] and ErbB receptors [22]. NRG1β,
particularly when its secretion is induced by glucocorticoids,
stimulates ErbB2 receptor phosphorylation in epithelial type II
cells [8]. Because ErbB2 has no known ligand it must act as a
heterodimer partner of ligand-bound ErbB1, ErbB3, or ErbB4.
The activation of ErbB2 by NRG1β in type II cells suggests
heterodimerization of ErbB2 with ErbB3 or ErbB4.
Little is known about ErbB receptor dimerization in fetal
lung fibroblasts and type II cells. We hypothesized that specific
ErbB receptor dimers are significant for fibroblast–type II cell
communication that controls late gestation lung development.
We therefore studied ErbB receptor protein content, dimeriza-
tion, phosphorylation, and co-localization patterns in primary
cultures of fetal E19 rat lung fibroblasts and alveolar epithelial
type II cells. Our experiments were done in untreated cells as
well as in EGF-, transforming growth factor alpha (TGFα)-,
NRG1β-, fibroblast conditioned medium (FCM)-, and type II
cell conditioned medium (T2CM)-treated cells. We also used
siRNA to downregulate ErbB4 in fetal lung fibroblasts to study
the effect on fibroblast-type II cell communication.
2. Materials and methods
Timed-pregnant Sprague–Dawley rats were obtained from Taconic Farms
(Germantown, NY); Dulbecco's modified eagle's medium (DMEM), Hanks
balanced salt solution (HBSS), and DNAse were from Gibco (Grand Island,
NY); plastic tissue culture dishes, flasks and six-well tissue culture plates were
from Falcon/Becton Dickinson (Franklin Lakes, NJ); charcoal-stripped fetal calf
serum (FCS) was from Hyclone (Logan, UT); mouse monoclonal anti-actin
clone AC-40, epidermal growth factor (EGF), and TGFα were from Sigma (St.
Louis, MO); ErbB4 siRNAs, scrambled siRNA, GAPDH siRNA and mouse anti
GAPDH antibody were from Ambion (Austin, TX); transfection reagent TKO
was fromMirus (Madison, WI); HRP-labeled goat anti-rabbit IgG and goat anti-
mouse IgG were from Perkin Elmer Life Sciences, Inc (Boston, MA); rabbit
polyclonal IgG antibodies to EGFR (1005), ErbB-3 (C-17), and ErbB-4 (C-18),
SK-BR-3 cell lysate and Blotto were from Santa Cruz Biotechnology (Santa
Cruz, CA); rabbit polyclonal antibody c-erbB-2 (Ab-1), mouse monoclonal
antibodies c-erbB-2 (Ab-17), and c-erbB-3 (Ab-6) were from LabVision
(Fremont, CA); rabbit polyclonal IgG antibody was from Zymed (South San
Francisco, CA); protein A Sepharose™ CL-4B was from Amersham
Biosciences (Uppsala, Sweden); Precision Plus Protein™ standards (dual
color) and nitrocellulose membranes were from Bio-Rad Laboratories
(Hercules, CA); recombinant horseradish peroxidase-linked anti-phosphotyr-
osine antibody RC20 was from Transduction Laboratories (Palo Alto, CA);
NRG1β producer cells were a generous gift from Dr. Kermit Carraway, III, (UC
Davis, CA). NRG1β was purified from cultured cells by Dr. Ann Kane of the
Center for Gastroenterology Research in Absorptive and Secretory Processes
(GRASP) at Tufts–New England Medical Center.
2.1. Fetal rat lung fibroblast and epithelial type II cell cultures
The animal research protocol was approved by the institutional IACUC.
Pregnant rats were sacrificed by CO2 inhalation at E19 of gestation (term E22).Table 1
Rat ErbB4 siRNA sequences
ErbB4 siRNA Target rat ErbB4 mRNA sites Sense s
Site 1 404–422 GGAA
Site 2 661–680 GGAC
Site 3 2063–2081 GGAAThe fetuses were removed and sex determined [26]. The lungs were removed,
pooled according to sex, minced into 1 mm3 pieces and dissociated in Hanks
buffered saline solution (HBSS) containing DNAse (20 μg/ml) and 0.25%
trypsin at 37 °C for 10 min. The dissociation was stopped by adding DMEM
with 10% charcoal stripped fetal calf serum (FCS−). The cells were filtered
through a sterile 45-μm cell strainer and centrifuged at 650×g for 10 min at 4 °C.
The cell pellets were resuspended in DMEMwith 10% FCS− and total cells were
plated at 6×106 /dish in 100 mm2 culture dishes for 60 min at 37 °C to allow for
lung fibroblast adherence.
For type II cell cultures, medium containing the non-adherent cells was
removed, pooled from both sexes, and centrifuged at 650×g for 10 min at 4 °C.
Cell pellets were resuspended in DMEM with 20% FCS−. The cells were plated
in 125 mm2 flasks and incubated for 60 min at 37 °C to allow a second
differential adherence. The non-adherent cells were collected, centrifuged as
described above, resuspended in DMEM with 20% FCS−, and plated into 12
well tissue culture plates (4×106 cells/well) or 6 well plates (6×106 cells/well)
and cultured in 37 °C, 5% CO2 incubator overnight. The non-adherent cells were
washed away with DMEM. The purity of the type II cells was determined by
methods of Post and Smith [29], preparations with greater than 92% purity were
used for experiments.
2.2. Fibroblast and epithelial type II cell conditioned medium
When fibroblasts or type II cells reached 90% confluence the cells were
serum starved for 24 h in serum-free medium. This medium was collected from
fibroblasts as fibroblast conditioned medium (FCM) and from type II cells as
type II cell conditioned medium (T2CM).
2.3. siRNA experiments
The fibroblasts were plated in 6 well plates at 15×104/well or 24 well plates
at 3.5×104/well to obtain 50% confluence next day. Three different ErbB4
siRNAs which target the rat ErbB4 mRNA sequences 404–422 (site 1), 661–
680 (site 2) and 2063–2081 (site 3) were used (Table 1), together with the
transfection reagent Transit-TKO. Scrambled siRNAwas used for a nonspecific
control. The initial transfection lasted 48 h. siRNAs were then added with serum
free medium for the last 24 h and the media collected as FCM that was used to
treat type II cells at the 1:1 ratio to DMEM.
2.4. 3H-Choline incorporation
Confluent type II cell cultures were treated with 0.5 μCi 3H-choline for 24 h.
Cells were washed 3 times with ice cold PBS, scraped in PBS and sonicated.
Aliquots in duplicate were used for protein determination. Following lipid
extraction with chloroform and methanol, disaturated phosphatidylcholine
(DSPC) was isolated by osmium tetroxide and separated by thin-layer
chromatography on silica gel H chromatography sheets. The resulting spots
were scraped into scintillation fluid, counted in a beta scintillation counter,
expressed as disintegrations per min per μg protein, and normalized as percent of
experiment specific controls.
2.5. Co-immunoprecipitation (co-IP) and Western blotting of the ErbB
receptors
The cells were stimulated with EGF (17 nM) for 3 min, TGFα (18 nM) for
5 min, NRG1β (33 nM) for 2 min, or serum-free DMEM (controls) for 3 min.
Alternatively, fibroblasts were exposed for 24 h to T2CM, and type II cells wereequences 5′–3′ Anti-sense sequences 5′–3′
AGAUGGCAACUUUGGtt CCAAAGUUGCCAUCUUUCCtg
UGUGUGUGCAGAACAtt UGUUCUGCACACACAGUCCtt
GAGCAUCAAAAAGAAtt UUCUUUUUGAUGCUCUUCCtt
Fig. 1. ErbB receptors in rat fetal lung fibroblasts and alveolar epithelial type II
cells. (A) Representative blots of phosphorylated (upper panel) and total ErbB1,
ErbB2, ErbB3, ErbB4 (middle panels), and actin (lower panel) in female
fibroblasts (left side) and alveolar type II cells (right side). (B) Densitometric
analysis of ErbB receptor protein amounts. Values represent the ratio of receptor
protein to β actin, Mean±SEM, N=7, *Pb0.05.
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and lysed in co-IP buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM MgCl2,
0.1% Triton X-100, 10% glycerol, 1 mM Na3VO4, 1 mM NaF, 1 mM ZnCl2,
10 mM β-glycerol phosphate, 5 mM tetrasodium pyrophosphate, 1 mM
phenylmethylsulfonyl fluoride, and 4 μg/ml each of aprotinin, leupeptin and
pepstatin). Duplicate aliquots were used for protein determination [20]. 500 μg
of total fibroblast protein or 300 μg of total type II cell protein were incubated
for 90 min at 4 °C with 2 μg of the specific receptor antibody (anti-EGFR 1005,
anti-ErbB2 Ab1, anti-ErbB3 C17, anti-ErbB4 C18, or rabbit polyclonal IgG).
Protein-A-Sepharose was added and the incubation was continued at 4 °C
overnight. The beads were collected by microcentrifugation at 100×g and 4 °C
for 30 s, washed three times with co-IP washing buffer (20 mM HEPES (pH
7.4), 150 mM NaCl, 1 mM EDTA, 0.1% Triton X-100, 1 mM Na3VO4, 1 mM
NaF, 10 mM β-glycerol phosphate, 5 mM tetrasodium pyrophosphate, 0.2 mM
phenylmethylsulfonyl fluoride, and 4 μg/ml each of aprotinin, leupeptin, and
pepstatin), and boiled in Laemmli sample loading buffer for 5 min at 100 °C.
The immunoprecipitated protein and paired lysates were separated by 7% SDS-
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes.
Ponceau staining was used to confirm equal protein loading. The blots were
blocked in 1% BSA and incubated with recombinant horseradish peroxidase-
linked anti-phosphotyrosine antibody RC20 (1:5000) overnight at 4 °C, washed
three times with TBST, and bands visualized by enhanced chemiluminescence.
Membranes were stripped in stripping buffer (62.5 mM Tris (pH 6.8), 2% SDS,
0.8% beta-mercaptoethanol) for 30 min at 50 °C, blocked with 5% non-fat milk
and reprobed with an antibody against one of the other ErbB receptors (EGFR
Ab1005, ErbB2 Ab17, ErbB3 Ab6, or ErbB4 C18), or actin Ab (clone AC-40)
overnight at 4 °C. Appropriate secondary antibody was applied and bands were
visualized by enhanced chemiluminescence. Membranes were stripped for
reprobing up to a maximum of 4–5 times. Densitometry was performed, and the
readings for bands of phosphorylation were divided by the total receptor protein
to determine activation per receptor amount.
2.6. Confocal microscopy
Primary rat type II cells were cultured on glass cover slips. After 24 h serum
starvation, cells were treated with FCM, NRG1β (33 nM) or DMEM (controls)
for 24 h. Immunofluorescence was done as described [28]. Cells were rinsed
with DMEM, fixed for 20 min in 3% paraformaldehyde and permeabilized for
2 min with 0.2% Triton X-100 in PBS. After blocking in 10% normal goat
serum, cells were incubated with primary ErbB-antibody (EGFR Ab1005,
ErbB2 Ab15, ErbB2 Ab1, ErbB3 C17, ErbB3 Ab5, ErbB4 C7) for 30 min at
room temperature, washed with PBS and incubated with secondary antibody
(Alexa Fluor 488, Alexa Fluor 568) for 30 min at room temperature. Cells were
mounted in Gelvatol/DABCO and analyzed using a Leica TCS–SP2 confocal
laser scanning microscope.
2.7. Data analysis
Data are presented as Mean+SEM unless otherwise stated. Densitometry
was used to quantitatively analyze Western blots of IPs. Statistical analyses were
performed using either paired two-sample t-tests or one-way analysis of
variance (ANOVA) followed by Dunnett's multiple comparison test to correct
for multiple comparisons of individual treatments versus control (Instat
Statistical Package, Graphpad Software Inc., San Diego, CA).3. Results
3.1. Expression pattern of the four ErbB receptors
All four ErbB receptors were expressed in fetal lung fibro-
blasts and type II cells (Fig. 1A). The Western blots of ErbB
receptors were quantitated by densitometry and normalized to β
actin to correct for loading variability. Densitometry of female
and male lung fibroblasts identified no differences in receptor
protein amount for all four receptors. We therefore combinedthe quantitative data from both sexes. Compared to the expres-
sion in fibroblasts, three of four ErbB receptors appeared more
abundant in the fetal type II cells. This was statistically sig-
nificant for ErbB1, ErbB2, and ErbB3. ErbB1 receptor protein
was 68±22 densitometry units (units) in type II cells compared
to 51±16 units in fibroblasts (N=7, P=0.0005), ErbB2 was
61±15 units in type II cells and 39±8.7 units in fibroblasts
(N=7, P=0.009), ErbB3 was 93±9 units in type II cells and
41±9 units in fibroblasts (N=7, P=0.002), ErbB4 was 42±11
units in type II cells and 46±14 units in fibroblasts (N=7, P=
0.18) (Fig. 1B), revealing cell specific ErbB receptor expression
patterns.
3.2. ErbB receptor heterodimerization and phosphorylation in
response to growth factors in E19 fetal rat lung fibroblasts and
epithelial type II cells
Co-immunoprecipitation (Co-IP) was used to determine the
heterodimers formed in the fetal rat lung fibroblasts and type II
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in response to stimulation with different ErbB ligands. The
signals were quantified by densitometry. The growth factor-
induced phosphorylated proportion of total ErbB protein was
compared to that of the untreated cells. To exclude non-specificFig. 2. Co-immunoprecipitation of ErbB receptor heterodimers in response to growth
Cells were unstimulated (control) or stimulated with EGF, TGFα, or NRG1β and im
ErbB4 (D, H) or IgG (I) under co-immunoprecipitation conditions. Panels show repr
illustrated results were consistently found in 4–5 independent experiments.binding, antibody to IgG was also used for Co-IP. All blots were
probed with antibodies to phosphotyrosine and reprobed for
each ErbB receptor. Co-IP with the irrelevant IgG antibody did
not reveal any ErbB signals, demonstrating the specificity of our
ErbB Co-IP results (Fig. 2I).factor stimulations in rat fetal lung fibroblasts and alveolar epithelial type II cells.
munoprecipitated with antibody to ErbB1 (A, E), ErbB2 (B, F), ErbB3 (C, G),
esentative blots for fibroblasts (A, B, C, D and I) and type II cells (E, F, G, H);
Table 2
Co-IP densitometry of phosphorylated signals of ErbB dimers
EGF TGFα NRG1β ANOVA
Fibroblasts
Co-IP ErbB1
ErbB4 phosphorylation 187±22** 165±12* 116±17 P=0.001
ErbB1 phosphorylation 301±32** 235±34** 157±12 Pb0.0001
Co-IP ErbB2
ErbB4 phosphorylation 234±49** 126±12 99±11 P=0.001
ErbB2 phosphorylation 176±33 116±8 123±25 P=0.13
Co-IP ErbB3
ErbB4 phosphorylation 192±44 166±32 142±3 P=0.27
ErbB3 phosphorylation 196±38* 137±15 127±18 P=0.21
Co-IP ErbB4
ErbB4 phosphorylation 161±30 172±41 131±15 P=0.09
Type II cells
Co-IP ErbB1
ErbB4 phosphorylation 199±68 137±15 127±18 P=0.21
ErbB2 phosphorylation 308±52 172±±47 170±50 P=0.15
ErbB1 phosphorylation 118±17 105±4 89±21 P=0.58
Co-IP ErbB2
ErbB4 phosphorylation 115±4* 87±3 79±5** Pb0.0001
ErbB2 phosphorylation 109±8 110±9 97±12 P=0.34
Co-IP ErbB3
ErbB4 phosphorylation 166±41 119±22 133±2 P=0.57
ErbB2/3 phosphorylation 117±7 115±9 141±19 P=0.22
Co-IP ErbB4
ErbB4 phosphorylation 103±28 103±28 102±2 P=0.99
ErbB1 phosphorylation 109±11 116±22 123±11 P=0.36
Values are percentage of treatment phosphorylation signals over the receptor
proteins and then normalized to the experiment control, Mean±SEM. (N=4–5
experiments). P value for the ANOVA is shown. *Pb0.05, **Pb0.001 com-
pared to unstimulated control, Dunnett multiple comparison test.
Table 3
Summary of major heterodimers of ErbB receptors in fetal lung cells
Fibroblasts Type II cells
ErbB1 ErbB4 ErbB4, ErbB2
ErbB2 ErbB4 ErbB4
ErbB3 ErbB4 ErbB4, ErbB2
ErbB4 – ErbB1
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protein amounts between male and female fetal lung fibroblasts,
we used female fibroblasts for the Co-IP experiments. In female
fibroblasts, antibody to ErbB1 co-immunoprecipitated ErbB4
(Fig. 2A). Compared to untreated fibroblasts, stimulation with
EGF increased the phosphorylated proportion of both precip-
itated ErbB1 (301±22%, N=5, Pb0.01) and co-precipitated
ErbB4 (187±22%, N=5, Pb0.01), while TGFα increased
ErbB1 phosphorylation proportion (235±34%, N=5, Pb0.01)
and co-immunoprecipitated ErbB4 (165±12%, N=5, Pb0.05)
(Table 2). Antibody to ErbB2 co-immunoprecipitated ErbB4.
The co-precipitated ErbB4 had a significant increase in
phosphorylation proportion after EGF treatment (234±49%,
N±5, Pb0.01), when compared to untreated cells (Fig. 2B;
Table 2). Antibody to ErbB3 co-precipitated ErbB4 (Fig. 2C).
Precipitated ErbB3 phosphorylation proportion was significant-
ly increased by EGF (196±38%, N=5, Pb0.05). Surprisingly,
Co-IP with antibody to ErbB4 only revealed immunoprecipi-
tation of ErbB4. No other ErbB receptor was detected on
Western blot. EGF, TGFα, and NRG1β each slightly stimulated
phosphorylation proportion of the precipitated ErbB4 receptor,
but this was not statistically significant (Fig. 2D; Table 2).
ErbB4 receptor was co-immunoprecipitated with ErbB1,
ErbB2, and ErbB3 antibodies in fetal type II cells (Fig. 2E–G).
Fetal type II cells differed from fibroblasts in their Co-IP patterns
in two ways. First, antibody to ErbB1 and to ErbB3 each co-precipitated ErbB2 in addition to ErbB4 (Fig. 2E, G). Second,
antibody to ErbB4 co-precipitated ErbB1 (Fig. 2H).When type II
cells were stimulated with EGF, TGFα, or NRG1β, there was a
smaller stimulation of the phosphorylated proportion of both the
primary receptor and the co-precipitated dimers (Table 2).
These Co-IP results for both fibroblasts and type II cells were
found in each of 5 and 3–4 separate experiments, respectively,
and in no instance did we observe a heterodimer partner in fewer
than this number of separate experiments. Table 3 summarizes the
ErbB receptor dimerization patterns for female fetal lung
fibroblasts and type II cells. Overall, ErbB4 appeared to be the
common heterodimer partner in both fibroblasts and type II
epithelial cells of the fetal rat lung. Table 2 summarizes the
densitometry analysis of phosphorylation of the co-precipitated
ErbB receptor dimers in response to stimulation by EGF, TGFα,
and NRG1β. Analysis of phosphorylation responses by ANOVA
confirmed the reproducibility of finding specific Co-IP partners.
3.3. ErbB receptor heterodimerization and phosphorylation in
fibroblast-epithelial type II cell communication in E19 fetal rat
lungs
The above Co-IP experiments demonstrated the reproducible
appearance of specific heterodimer partners with changes in
receptor phosphorylation in response to ligand stimulation. In
order to provide more insight into the role of ErbB receptor
heterodimerization and phosphorylation in fibroblast-epithelial
type II cell communication in fetal lung development, we
studied the ErbB receptor heterodimerization and phosphory-
lation in E19 fetal rat fibroblasts and type II cells at baseline and
after treatment with conditioned medium from the opposite cell
type. T2CM treatment of fibroblasts, and FCM treatment of type
II cells for 24 h produced the same dimer patterns as that with
growth factor stimulation (Fig. 3). Table 4 summarizes the
densitometry analysis of the phosphorylated proportion of total
protein and amount of total receptor protein of both precipitated
and co-precipitated ErbB receptor dimers in response to the
conditioned media. In fibroblasts with T2CM treatment, the
ErbB1 protein amounts were significantly decreased to 77±7%
(N=5, Pb0.05), compared to the untreated cells. In the contrary
FCM stimulated type II cell ErbB1 receptor protein amount to
167±12% (N=4, Pb0.05) of untreated cells when immuno-
precipitated with an antibody to ErbB1 and to 204±10% (N=3,
Pb0.05) of untreated cells when immunoprecipitated with an
antibody to ErbB4. These data suggest that the ErbB1/ErbB4
dimers play an important role in the mesenchyme–epithelial
communication in E19 fetal rats. The conditioned media
treatments did not change the dimer patterns in the fibroblasts
and type II cells.
Fig. 3. Co-immunoprecipitation of ErbB receptor heterodimers in fibroblast-epithelial communication in rat fetal lung. Cells were treated with the conditioned medium
from opposite cell types and immunoprecipitated with antibody to ErbB1 (A, E), ErbB2 (B, F), ErbB3 (C, G), and ErbB4 (D, H) under coimmunoprecipitation
conditions. Panels show representative blots for fibroblasts (A, B, C, D) and type II cells (E, F, G, H); illustrated results were consistently found in 3–5 independent
experiments.
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Table 4
The phosphorylation and protein amount of ErbB receptors and the heterodimers in fetal rat fibroblasts and type II cells in response to a 24-h treatment with
conditioned medium from the opposite cell type
Dimers ErbB1 ErbB2 ErbB3 ErbB4
IP Ptyr protein Ptyr protein Ptyr protein Ptyr protein
Fibroblasts
ErbB1 170±36 77±7# 118±27 87±13
ErbB2 137±35 65±21# 112±57 106±12
ErbB3 96±14 126±26 171±74 114±19
ErbB4 80±18 112±41
Type cells
ErbB1 86±10 167±12# 292±130 111±11 126±25 107±8
ErbB2 86±2 116±12 76±3* 139±10
ErbB3 119±16 102±14 119±16 99±7 127±44 106±15
ErbB4 81±19 204±10# 110±4 139±1
Receptor protein values are percentage of treatment signals over control. Phosphorylation values represent proportion of phosphorylated signal over total receptor
protein normalized to the experimental control. Data are Mean±SEM, N=3–5; *Pb0.05 compared to unstimulated control with Dunnett multiple comparison test (to
correct for using controls for 4 treatment corrections). #Pb0.05 compared to unstimulated control with paired t-test. Ptyr: Phosphotyrosine.
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lipid synthesis in type II cells
ErbB4 was a common dimer partner for each of the other
ErbB receptors, and the studies with conditioned media
suggested that the ErbB1/ErbB4 dimer was an important ErbB
heterodimer in mesenchyme–epithelial communication. There-
fore we further investigated the importance of ErbB4 in
mesenchyme–epithelial communication by gene silencing of
ErbB4 with small interfering RNA (siRNA) in fibroblasts. The
ErbB4 receptor protein amount in fibroblasts was downregulated
to 77±5% (N=8, Pb0.05) by transfection with ErbB4 siRNAs
compared to scrambled siRNA treatment (Fig. 4A, B). During
the final 24 h of ErbB4 downregulation FCMwas collected from
the fibroblasts and used to treat type II cells. The synthesis of
surfactant phospholipid was measured by assay of incorporated
3H choline into DSPC. Treatment of the type II cells with FCM
from the fibroblasts with ErbB4 siRNA treatment increased
choline incorporation into DSPC by 43±13% (N=24, Pb0.01)
over the treatment with FCM from scrambled siRNA (Fig. 4C).
These data imply that the inhibition of ErbB4 in the fibroblasts
may promote the release of factors that stimulate the synthesis of
surfactant phospholipids in type II cells.
3.5. Localization of ErbB receptors in fetal rat lung type II cells
Confocal fluorescence microscopy was used to investigate
the effects of NRG1β and FCM on cellular localization and co-
localization of the most common dimerization partner, ErbB4,
in the epithelial type II cells. We focused these studies on type II
cells because of their importance for fetal lung surfactant
synthesis and also because of the broad impact of ErbB ligands
and FCM on ErbB4 receptor phosphorylation in type II cells. In
untreated type II cells, ErbB4 was diffusely localized in the
nuclear region and showed a less intense signal in the cytoplasm
(Fig. 4A–C, green fluorescent color, left panels). ErbB1 and
ErbB2 were also mainly localized in the nuclei (Fig. 4A, B, red
fluorescent color), whereas ErbB3 appeared as discrete clumps
in the nuclei suggestive of nucleolar localization (Fig. 4C, redfluorescent color). In the absence of treatment there was some
evidence of co-localization of ErbB4 and ErbB2, but little
visible evidence for co-localization with the other receptors.
Exposure to NRG1β for 24 h led to a relocation of all ErbB
receptors out of the nucleus into the cytoplasm (Fig. 4A–C,
middle panels). Exposure to FCM did not change the cellular
localization of ErbB4, but induced relocalization of ErbB1 and
ErbB3 out of the nucleus (Fig. 4A, C, red fluorescent color,
right panels). ErbB2 localization was also not dramatically
changed by FCM compared to the untreated cells (Fig. 4B, red
fluorescent color, right panel), intensifying the co-localization
of both receptors.
4. Discussion
4.1. ErbB receptor heterodimerization and phosphorylation in
late developing lungs
In this study, we found that the four ErbB receptors are
present in both fibroblasts and alveolar epithelial type II cells of
late gestational fetal rat lung. Their expression patterns and
responses to ligand stimulation are cell- and ligand-specific,
with a stronger expression of ErbB1, ErbB2, and ErbB3 in
alveolar epithelial type II cells. ErbB receptor function is
recognized to have a significant role in the development and
propagation of several types of cancer, including lung cancers
[42]. Studies have focused on the heterodimerization dynamics
of ErbB receptors using both tumor cell lines and cell lines
engineered to express only specific ErbB receptors [41]. Such
studies have identified ErbB2 as the preferred heterodimeriza-
tion partner for each of the other three ErbB receptors [5,13]. In
contrast, in this study we found in the developing rat lung that
ErbB4 is the most common heterodimerization partner. There
are important differences between tumor cell lines, engineered
cell lines, and primary fetal cells that would lead one to expect
differences in results. Our findings correlate with functional
results in other systems. For example in the reproductive sys-
tem, ErbB1 and ErbB4 must act in concert in the development
of adult reproductive function for rat female sexual differentia-
Fig. 4. ErbB4 downregulation in fibroblasts and the effect of FCM from
the ErbB4 downregulated fibroblasts on DSPC synthesis in type II cells.
(A) Representative blots of total ErbB4 receptor proteins (upper panel) and β
actin (lower panel) in female fibroblasts. #Scr: scrambled siRNA, siB4: ErbB4
siRNAs. (B) Densitometric analysis of ErbB4 receptor protein amounts in
fibroblasts. Values (Mean±SEM, N=8) represent the ratio of receptor protein to
β actin and then normalized by scrambled siRNA treatments. *Pb0.05. (C) 3H
Choline incorporation into DSPC in type II cells. Values represent ratio of DPM
to protein amounts and then normalized by scrambled siRNA treatments.Mean±
SEM, N=24. **Pb0.01.
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dimerization of ErbB4 with other ErbB receptors forms a high
affinity binding complex which enhances the level of auto-
phosphorylation and results in a significant modification of the
ligand-induced biological response [10,31,38]. There is a
general impression that ErbB4 expression is found within
more differentiated compartments. Given its widespread expres-
sion in embryonic as well as adult tissue a regulatory function in
multiple systems would not be surprising [3]. ErbB2, which has
no known ligand, must dimerize with a ligand-activated ErbB
receptor to signal its effect [17,39]. It is possible that in fetal
type II cells NRG1β, which is secreted by lung fibroblasts andfound in the FCM [8], signals some effects on surfactant
synthesis through ErbB2/ErbB4 dimers such as we identified in
this study.
ErbB4 was consistently co-immunoprecipitated with other
ErbB receptors and was clearly visible by Western blotting in
both rat fetal lung fibroblasts and type II cells, however Western
blot did not show the presence of any other ErbB receptors in
fibroblasts after co-immunoprecipitation with ErbB4 antibody.
We can postulate two possible reasons for this observation, both
related to the possible stoichiometry of heterodimer formation.
One possibility is that when immunoprecipitating with antibody
for another receptor, e.g. ErbB1, the vast majority of ErbB1
heterodimers were with ErbB4, so ErbB4 could readily be
detected on Western blot, whereas when immunoprecipitating
with antibody for ErbB4, its heterodimers were split among
ErbB1, ErbB2, and ErbB3 such that the relative proportions of
these co-precipitants was too low to be detected on Western
blot. The second possible reason for the lack of ErbB4 co-
precipitants in fibroblasts may be the three-dimensional struc-
tural change of the dimers after antibody binding [7,11].
Different antibodies may bind at different sites of the complex,
changing the conformation and affect the dimer stability,
leading to inconsistent results in both directions. However the
stoichiometry of the ligands and receptors in the heterodimer
complexes are unknown. Further studies on the structural level
of ErbB heterodimerization will be needed to fully resolve this
issue.
EGF and TGFα are ligands for ErbB1, and NRG1β is a
ligand for both ErbB3 and ErbB4. These ligands can activate
their homo- or heterodimers [9,41]. It has been suggested that
the ErbB heterodimers may form secondary heterotetramers
[15]. The formation of secondary hetero-oligomers can be
induced by a ligand for a third ErbB protein. Therefore EGF and
TGFα may stimulate the formation of 2/4 or 4/4 heterodimers
and phosphorylation via ErbB1. The third ErbB protein might
not be precipitated because of the small amount and weak
binding. Actually the heterodimerization of ErbB receptors and
the mechanism of phosphorylation have been proven more
complicated or diverse by interactions with some cell surface
receptors outside the ErbB family [36] and intracellular adaptors
and scaffolding systems [6,14,16].
4.2. ErbB receptor cellular localization in late developing
lungs
In our fluorescent confocal microscope studies in type II cells
all four ErbB receptors exhibited strong staining in the nuclei
and re-localized to the extra-nuclear cytoplasmic region after
NRG1β treatment. This effect was most prominent for ErbB4.
Since we studied the effect of a 24-h exposure to NRGwe cannot
compare the confocal localization data to the short-term (2 min)
stimulatory effect of NRG on receptor dimerization or
phosphorylation seen in co-immunoprecipitation. Compared to
NRG1β, FCM induced a differential effect on ErbB2 and
ErbB4, in which co-localization of these two receptors was
observed by confocal imaging. Surprisingly, even though ErbB4
precipitated with all other ErbB receptors in fetal type II cells
Fig. 5. Cellular localization of ErbB receptors in fetal rat alveolar epithelial type II cells. Confocal immunofluorescent microscopy was used to identify the cellular
localization of the major dimerization partner ErbB4 (green), with ErbB1 (red) (A), ErbB2 (red) (B), or ErbB3 (red) (C) under control conditions (left panels) and after
treatment with either NRG (middle panels) or FCM (right panels) for 24 h.
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ErbB2 and ErbB4 (Fig. 5B). Interestingly, 24-h exposure to
NRG led to a decrease in phosphorylation of the co-localized
ErbB4.
We did not observe polarization (apical versus basal) char-
acteristics, which likely is due to the fact that cells do not
develop polarization when cultured on plastic. Studies of ErbB1
immunostaining in sections of fetal lung show no evidence of
polarization of ErbB1 [34]. Both this feature and the lack of a
distinct membrane concentration of ErbB receptors has beenobserved under some conditions in other cell types by ourselves
[46] and by others [23,44]. A feature common to these
observations is ongoing receptor activation (i.e. phosphoryla-
tion) in culture. Thus, the confocal image result may reflect the
dynamic nature of the ErbB receptors in our experiments.
With NRG1β treatments, the majority of internalized
receptor is in the cytoplasm, indicating specific signal responses
to NRG1β. Others have shown that stimulation with ligands can
cause direct trafficking from membrane to cytoplasm and
nucleus [23,19,27]. The nuclear function of the ErbB receptors
746 W. Liu et al. / Biochimica et Biophysica Acta 1772 (2007) 737–747is just beginning to be understood. Our results are all consistent
with a role of ErbB receptors in the cell–cell communication
process controlling fetal lung maturation.
4.3. ErbB receptor regulation in mesenchyme–epithelial
communication in late developing lungs
Fetal lung maturation requires communication between the
mesenchyme and adjacent type II cells, which is mediated via
direct contact or soluble factors [40]. Conditioned medium from
type II cells significantly decreased ErbB1 and ErbB2 protein
content in fibroblasts, whereas FCM significantly stimulated
ErbB1 and ErbB4 protein content in type II epithelial cells. At
this time in lung development the surfactant stimulatory effect
of lung fibroblast secreted factors is just starting, requiring
glucocorticoid exposure to fully stimulate it. Structurally, there
is the development of mesenchymal condensation, such that a
specific subset of fibroblasts becomes closely associated with
the developing acinar structure and the type II cells [2]. This
subset of fibroblasts takes on the phenotype of lipofibroblasts,
which actively regulate type II cell maturation via production of
maturational factors. We speculate that T2CM at this time
contains factors which promote this remodeling and the
development of the lipofibroblast phenotype [37,43].
Loss of balance of ErbB receptors may lead to functional
changes. Downregulation of ErbB4 by ErbB4 siRNA in E19 rat
type II cells impairs surfactant synthesis [45]. Deletion of
pulmonary ErbB4 expression in cardiac rescued ErbB4
transgenic mice also impairs surfactant synthesis in late fetal
development (unpublished data). In this study, downregulation
of ErbB4 in fibroblasts caused increased type II cell surfactant
DSPC synthesis, suggesting that fibroblast-type II cell commu-
nication promoting surfactant synthesis is negatively regulated
in fibroblasts by ErbB4 activity. ErbB1/ErbB4 dimers may play
an important regulatory role in late fetal lung development.
Dimerization and activation of ErbB receptors are normally
triggered by binding with their ligands. The heterodimerization
and phosphorylation observed in untreated fibroblasts and type
II cells may be induced by autocrine mechanisms. This high
endogenous activity may make the primary pulmonary cells less
sensitive to exogenous growth factor stimulation than may be
observed in some cell lines (unpublished data).
We conclude that ErbB receptors are differentially expressed
in the fetal lung and that ErbB4 heterodimers are particularly
important in late gestation fetal lung development. The role of
ErbB4 heterodimers may be to distinctly control maturational
processes in both fibroblasts and type II cells to specifically
regulate the development of surfactant synthesis. Further
understanding of how ErbB receptors act in developing lung
should provide important insight into how the development of
surfactant synthesis is regulated.
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